Luke Evnin Sells 30,616 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 30,616 shares of the company’s stock in a transaction that occurred on Wednesday, January 14th. The stock was sold at an average price of $0.57, for a total value of $17,451.12. Following the sale, the director directly owned 2,236,055 shares of the company’s stock, valued at $1,274,551.35. The trade was a 1.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Luke Evnin also recently made the following trade(s):

• On Thursday, January 15th, Luke Evnin sold 37,413 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.55, for a total transaction of $20,577.15.
• On Tuesday, January 13th, Luke Evnin sold 43,198 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.55, for a total transaction of $23,758.90.
• On Monday, January 12th, Luke Evnin sold 58,980 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.57, for a total transaction of $33,618.60.
• On Friday, January 9th, Luke Evnin sold 24,678 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.61, for a total transaction of $15,053.58.
• On Thursday, January 8th, Luke Evnin sold 7,716 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.63, for a total transaction of $4,861.08.
• On Wednesday, January 7th, Luke Evnin sold 11,915 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total transaction of $7,625.60.
• On Tuesday, January 6th, Luke Evnin sold 40,761 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.65, for a total value of $26,494.65.
• On Monday, January 5th, Luke Evnin sold 18,378 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total value of $11,761.92.
• On Friday, January 2nd, Luke Evnin sold 18,568 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.63, for a total value of $11,697.84.
• On Wednesday, December 31st, Luke Evnin sold 24,962 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.62, for a total value of $15,476.44.

Werewolf Therapeutics Stock Performance

HOWL opened at $0.55 on Friday. The company has a quick ratio of 3.87, a current ratio of 3.87 and a debt-to-equity ratio of 0.73. The stock’s 50 day moving average price is $0.83 and its two-hundred day moving average price is $1.23. The firm has a market capitalization of $26.66 million, a P/E ratio of -0.34 and a beta of 0.77. Werewolf Therapeutics, Inc. has a 12-month low of $0.53 and a 12-month high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.03. On average, equities analysts forecast that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have issued reports on HOWL. Zacks Research lowered shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th. Bank of America lowered their price target on Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research note on Tuesday, November 18th. Citigroup downgraded Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a research report on Friday, December 19th. Finally, HC Wainwright decreased their price objective on Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating on the stock in a report on Friday, December 19th. Three investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Werewolf Therapeutics currently has an average rating of “Hold” and a consensus target price of $3.75.

Institutional Investors Weigh In On Werewolf Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Susquehanna International Group LLP grew its stake in shares of Werewolf Therapeutics by 16.9% in the 3rd quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock valued at $183,000 after purchasing an additional 13,439 shares during the period. Quadrature Capital Ltd acquired a new stake in Werewolf Therapeutics in the 2nd quarter valued at $28,000. Bank of America Corp DE grew its position in Werewolf Therapeutics by 1.2% in the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock valued at $2,321,000 after acquiring an additional 25,882 shares during the period. Qube Research & Technologies Ltd bought a new stake in Werewolf Therapeutics in the second quarter valued at $48,000. Finally, Bridgeway Capital Management LLC raised its stake in Werewolf Therapeutics by 157.7% during the second quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock worth $111,000 after acquiring an additional 62,414 shares in the last quarter. 64.84% of the stock is owned by institutional investors and hedge funds.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.